- Home
- FHTX
as 03-28-2025 4:00pm EST
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 227.5M | IPO Year: | 2020 |
| Target Price: | $13.17 | AVG Volume (30 days): | 99.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.58 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.52 - $10.25 | Next Earning Date: | 03-06-2025 |
| Revenue: | $22,602,000 | Revenue Growth: | -33.83% |
| Revenue Growth (this year): | 44.46% | Revenue Growth (next year): | 24.12% |
Latest Foghorn Therapeutics Inc. News
FHTX Breaking Stock News: Dive into FHTX Ticker-Specific Updates for Smart Investing
GlobeNewswire
6 days ago
Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR Meeting
Zacks
25 days ago
Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Lags Revenue Estimates
MT Newswires
25 days ago
Foghorn Therapeutics 2024 Net Loss Narrows, Revenue Declines -- Shares Slipping Late
GlobeNewswire
25 days ago
Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook
Simply Wall St.
a month ago
Institutional investors may adopt severe steps after Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) latest 14% drop adds to a year losses
Zacks
a month ago
Will Foghorn Therapeutics Inc. (FHTX) Report Negative Q4 Earnings? What You Should Know
GlobeNewswire
a month ago
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences
Zacks
2 months ago
Foghorn Therapeutics (FHTX) Soars 11.4%: Is Further Upside Left in the Stock?
Compare FHTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "FHTX Foghorn Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.